Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Diagnosis & Therapy
Published in: Molecular Diagnosis & Therapy 1/2012

01-02-2012 | Review Article

Assessing Gene-Gene Interactions in Pharmacogenomics

Authors: Hsien-Yuan Lane, Guochuan E. Tsai, Dr Eugene Lin

Published in: Molecular Diagnosis & Therapy | Issue 1/2012

Login to get access

Abstract

In pharmacogenomics studies, gene-gene interactions play an important role in characterizing a trait that involves complex pharmacokinetic and pharmacodynamic mechanisms, particularly when each involved feature only demonstrates a minor effect. In addition to the candidate gene approach, genome-wide association studies (GWAS) are widely utilized to identify common variants that are associated with treatment response. In the wake of recent advances in scientific research, a paradigm shift from GWAS to whole-genome sequencing is expected, because of the reduced cost and the increased throughput of next-generation sequencing technologies. This review first outlines several promising methods for addressing gene-gene interactions in pharmacogenomics studies. We then summarize some candidate gene studies for various treatments with consideration of gene-gene interactions. Furthermore, we give a brief overview for the pharmacogenomics studies with the GWAS approach and describe the limitations of these GWAS in terms of gene-gene interactions. Future research in translational medicine promises to lead to mechanistic findings related to drug responsiveness in light of complex gene-gene interactions and will probably make major contributions to individualized medicine and therapeutic decision-making.
Literature
1.
Bell JT, Wallace C, Dobson R, et al. Two-dimensional genome-scan identifies novel epistatic loci for essential hypertension. Hum Mol Genet 2006; 15:1365–74PubMedCrossRef
2.
Carlborg O, Haley CS. Epistasis: too often neglected in complex trait studies. Nature 2004; 5: 618–25
3.
Lin E, Hwang Y, Liang KH, et al. Pattern-recognition techniques with haplotype analysis in pharmacogenomics. Pharmacogenomics 2007; 8: 75–83PubMedCrossRef
4.
Lin E, Hwang Y, Chen EY. Gene-gene and gene-environment interactions in interferon therapy for chronic hepatitis C. Pharmacogenomics 2007; 8: 1327–35PubMedCrossRef
5.
Lin E, Hsu SY. A Bayesian approach to gene-gene and gene-environment interactions in chronic fatigue syndrome. Pharmacogenomics 2009; 10: 35–42PubMedCrossRef
6.
Johnson AD, O’Donnell CJ. An open access database of genome-wide association results. BMC Med Genet 2009; 10: 6PubMedCrossRef
7.
Christensen K, Murray JC. What genome-wide association studies can do for medicine. N Engl J Med 2007; 356: 1094–7PubMedCrossRef
8.
Need AC, Goldstein DB. Whole genome association studies in complex diseases: where do we stand? Dialogues Clin Neurosci 2010; 12: 37–46PubMed
9.
Wheeler DA, Srinivasan M, Egholm M, et al. The complete genome of an individual by massively parallel DNA sequencing. Nature 2008; 452: 872–6PubMedCrossRef
10.
11.
Tucker T, Marra M, Friedman JM. Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet 2009; 85: 142–54PubMedCrossRef
12.
McKinney BA, Reif DM, Ritchie MD, et al. Machine learning for detecting gene-gene interactions: a review. Appl Bioinformatics 2006; 5: 77–88PubMedCrossRef
13.
Motsinger AA, Ritchie MD, Reif DM. Novel methods for detecting epistasis in pharmacogenomics studies. Pharmacogenomics 2007; 8: 1229–41PubMedCrossRef
14.
Phillips PC. Epistasis: the essential role of gene interactions in the structure and evolution of genetic systems. Nat Rev Genet 2008; 9: 855–67PubMedCrossRef
15.
Cordell HJ. Genome-wide association studies: detecting gene-gene interactions that underlie human diseases. Nat Rev Genet 2009; 10: 392–404PubMedCrossRef
16.
Moore JH, Williams SM. Epistasis and its implications for personal genetics. Am J Hum Genet 2009; 85: 309–20PubMedCrossRef
17.
Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–75PubMedCrossRef
18.
Bellman R. Adaptive control processes. Princeton (NJ): Princeton University Press, 1961
19.
Moore JH, Williams SM. New strategies for identifying gene-gene interactions in hypertension. Ann Med 2002; 34: 88–95PubMedCrossRef
20.
Thornton-Wells TA, Moore JH, Haines JL. Dissecting trait heterogeneity: a comparison of three clustering methods applied to genotypic data. BMC Bioinformatics 2006; 7: 204–21PubMedCrossRef
21.
Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 2008; 40: 695–701PubMedCrossRef
22.
Ma DQ, Whitehead PL, Menold MM, et al. Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. Am J Hum Genet 2005; 77: 377–88PubMedCrossRef
23.
Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69: 138–47PubMedCrossRef
24.
Ritchie MD, Motsinger AA. Multifactor dimensionality reduction for detecting gene-gene and gene-environment interactions in pharmacogenomics studies. Pharmacogenomics 2005; 6: 823–34PubMedCrossRef
25.
Lin E, Chen PS, Chang HH, et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1167–72PubMedCrossRef
26.
Li MD, Lou XY, Chen G, et al. Gene-gene interactions among CHRNA4, CHRNB2, BDNF, and NTRK2 in nicotine dependence. Biol Psychiatry 2008; 64: 951–7PubMedCrossRef
27.
Lou XY, Chen GB, Yan L, et al. A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet 2007; 80: 1125–37PubMedCrossRef
28.
Jakobsdottir J, Conley YP, Weeks DE, et al. C2 and CFB genes in age-related maculopathy and joint action with CFH and LOC387715 genes. PLoS One 2008; 3: e2199PubMedCrossRef
29.
Chan IH, Tang NL, Leung TF, et al. Study of gene-gene interactions for endophenotypic quantitative traits in Chinese asthmatic children. Allergy 2008; 63: 1031–9PubMedCrossRef
30.
Lin E, Lin CG, Wang JY, et al. Gene-gene interactions among genetic variants from seven candidate genes with pediatric asthma in a Taiwanese population. Curr Topics Genet 2008; 3: 83–8
31.
Liu J, Sun K, Bai Y, et al. Association of three-gene interaction among MTHFR, ALOX5AP and NOTCH3 with thrombotic stroke: a multicenter case-control study. Hum Genet 2009; 125: 649–56PubMedCrossRef
32.
Lin E, Pei D, Huang YJ, et al. Gene-gene interactions among genetic variants from obesity candidate genes for nonobese and obese populations in type 2 diabetes. Genet Test Mol Biomarkers 2009; 13: 485–93PubMedCrossRef
33.
Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn’s disease patients. Clin Gastroenterol Hepatol 2009; 7: 972–80PubMedCrossRef
34.
Wu LS, Hsieh CH, Pei D, et al. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant 2009; 24: 3360–6PubMedCrossRef
35.
Lin E, Hong CJ, Hwang JP, et al. Gene-gene interactions of the brain-derived neurotrophic-factor and neurotrophic tyrosine kinase receptor 2 genes in geriatric depression. Rejuvenation Res 2009; 12: 387–93PubMedCrossRef
36.
Neuman RJ, Wasson J, Atzmon G, et al. Gene-gene interactions lead to higher risk for development of type 2 diabetes in an Ashkenazi Jewish population. PLoS One 2010; 5: e9903PubMedCrossRef
37.
Pae CU, Drago A, Patkar AA, et al. Epistasis between a set of variations located in the TAAR6 and HSP-70 genes toward schizophrenia and response to antipsychotic treatment. Eur Neuropsychopharmacol 2009; 19: 806–11PubMedCrossRef
38.
Du Y, Wan YJ. The interaction of reward genes with environmental factors in contribution to alcoholism in Mexican Americans. Alcohol Clin Exp Res 2009; 33: 2103–12PubMedCrossRef
39.
Beretta L, Santaniello A, van Riel PL, et al. Survival dimensionality reduction (SDR): development and clinical application of an innovative approach to detect epistasis in presence of right-censored data. BMC Bioinformatics 2010; 11: 416PubMedCrossRef
40.
Lin E, Hwang Y, Wang SC, et al. An artificial neural network approach to the drug efficacy of interferon treatments. Pharmacogenomics 2006; 7: 1017–24PubMedCrossRef
41.
Kung SY, Hwang JN. Neural networks for intelligent multimedia processing. Proc IEEE 1998; 86: 1244–72CrossRef
42.
Bishop CM. Neural networks for pattern recognition. Oxford: Clarendon Press, 1995
43.
Hastie T, Tibshirani R, Friedman JH. The elements of statistical learning. New York: Springer-Verlag, 2001
44.
Hirschhorn JN, Daly MI. Genome-wide association studies for common diseases and complex traits. Nature Review Genet 2005; 6: 95–108CrossRef
45.
North BV, Curtis D, Cassell PG, et al. Assessing optimal neural network architecture for identifying disease-associated multi-marker genotypes using a permutation test, and application to calpain 10 polymorphisms associated with diabetes. Ann Hum Genet 2003; 67: 348–56PubMedCrossRef
46.
Horstmann S, Lucae S, Menke A, et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010; 35: 727–40PubMedCrossRef
47.
Hsiao TJ, Wu LS, Huang SY, et al. Effect of the common G-866A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population. Mol Diagn Ther 2010; 14: 101–6PubMedCrossRef
48.
Corvol H, De Giacomo A, Eng C, et al. Genetic ancestry modifies pharmacogenetic gene-gene interaction for asthma. Pharmacogenet Genomics 2009; 19: 489–96PubMedCrossRef
49.
Choudhry S, Que LG, Yang Z, et al. GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. Pharmacogenet Genomics 2010; 20: 351–8PubMedCrossRef
50.
Sharma S, Das M, Kumar A, et al. Interaction of genes from influxmetabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics 2008; 18: 1041–9PubMedCrossRef
51.
Liou YJ, Bai YM, Lin E, et al. Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J 2012; 12: 54–61PubMedCrossRef
52.
Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095–105PubMedCrossRef
53.
Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005; 62: 1097–106PubMedCrossRef
54.
aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ 2009; 180: 305–13CrossRef
55.
Lin E, Chen PS, Lee IH, et al. Modeling short-term antidepressant responsiveness with artificial neural networks. Open Access Bioinformatics 2010; 2: 55–60CrossRef
56.
Lin E, Hwang Y, Tzeng CM. A case study of the utility of the HapMap database for pharmacogenomic haplotype analysis in the Taiwanese population. Mol Diagn Ther 2006; 10: 367–70
57.
Lekman M, Paddock S, McMahon FJ. Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Mol Diagn Ther 2008; 12: 321–30PubMedCrossRef
58.
59.
Lin E, Chen PS. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 2008; 9: 935–46PubMedCrossRef
60.
Lin E, Hsu SY. Gender differences and pharmacogenomics with antidepressants in depression. In: Hernandez P, Alonso S, editors. Women and depression. New York: Nova Science Publishers, 2009
61.
Lin E, Chen PS, Huang LC, et al. Association study of a brain-derived neurotrophic-factor polymorphism and short-term antidepressant response in major depressive disorders. Pharmacogenomics Personalized Med 2008; 1: 1–6CrossRef
62.
Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther 2009; 124: 57–73PubMedCrossRef
63.
64.
Siffert W. G protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annu Rev Med 2005; 56: 17–28PubMedCrossRef
65.
66.
Norton N, Owen MJ. HTR2A: association and expression studies in neuropsychiatric genetics. Ann Med 2005; 37: 121–9PubMedCrossRef
67.
Serretti A, Drago A, De Ronchi D. HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem 2007; 14: 2053–69PubMedCrossRef
68.
McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78: 804–14PubMedCrossRef
69.
Parsons MJ, D’Souza UM, Arranz MJ, et al. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry 2004; 56: 406–10PubMedCrossRef
70.
Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386–9PubMedCrossRef
71.
Sharma B, Henderson DC. Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother 2008; 9: 2161–73PubMedCrossRef
72.
Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag 2009; 5: 441–52PubMed
73.
Grudell AB, Sweetser S, Camilleri M, et al. A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. Gastroenterology 2008; 135: 1142–54PubMedCrossRef
74.
Hauner H, Meier M, Jöckel KH, et al. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics 2003; 13: 453–9PubMedCrossRef
75.
Hsiao DJ, Wu LS, Huang SY, et al. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the guanine nucleotide binding protein beta polypeptide 3 gene. Pharmacogenet Genomics 2009; 19: 730–3PubMedCrossRef
76.
Vazquez Roque MI, Camilleri M, Clark MM, et al. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. Clin Gastroenterol Hepatol 2007; 5: 829–37PubMedCrossRef
77.
Hsiao TJ, Wu LS, Huang SY, et al. A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity. Clin Pharmacol Adv Applic 2010; 2: 105–10
78.
Lane HY, Tsai GE, Lin E. Research highlights from the latest articles in 5-HTTLPR pharmacogenomics. Personalized Med 2010; 7: 139–41CrossRef
79.
Lin E, Chen PS. Molecular genetics of human personality traits for psychiatric, behavioral, and substance-related disorders. Open Translat Med J 2009; 1: 1–8CrossRef
80.
81.
82.
Hwang Y, Chen EY, Gu ZJ, et al. Genetic predisposition of responsiveness to therapy for chronic hepatitis C. Pharmacogenomics 2006; 7: 697–709PubMedCrossRef
83.
Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt-88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000; 43: 124–7PubMedCrossRef
84.
Yee LJ, Tang J, Gibson AW, et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33: 708–12PubMedCrossRef
85.
Sugimoto Y, Kuzushita N, Takehara T, et al. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J Viral Hepat 2002; 9: 377–84PubMedCrossRef
86.
Ke WS, Hwang Y, Lin E. Pharmacogenomics of drug efficacy in the interferon treatment of chronic hepatitis C using classification algorithms. Adv Appl Bioinform Chem 2010; 3: 39–44PubMed
87.
Kitamura A, Takahashi K, Okajima A, et al. Induction of the human gene for p44, a hepatitis C-associated microtubular aggregate protein, by interferon-α/gb. Eur J Biochem 1994; 224: 877–83PubMedCrossRef
88.
Hallen LC, Burki Y, Ebeling M, et al. Antiproliferative activity of the human IFN-alpha-inducible protein IFI44. J Interferon Cytokine Res 2007; 27: 675–80PubMedCrossRef
89.
Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2007; 14: 10–22PubMedCrossRef
90.
Lin XY, Choi MS, Porter AG. Expression analysis of the human caspase-1 subfamily reveals specific regulation of the CASP5 gene by lipopolysaccharide and interferon-gamma. J Biol Chem 2000; 275: 39920–6PubMedCrossRef
91.
Dong LM, Brennan P, Karami S, et al. An analysis of growth, differentiation and apoptosis genes with risk of renal cancer. PLoS One 2009; 4: e4895PubMedCrossRef
92.
Ulybina YM, Kuligina ESh, Mitiushkina NV, et al. Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer. Cancer Lett 2009; 278: 183–91PubMedCrossRef
93.
Quaye L, Dafou D, Ramus SJ, et al. Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Hum Mol Genet 2009; 18: 1869–78PubMedCrossRef
94.
Ulybina YM, Kuligina ESh, Mitiushkina NV, et al. Evidence for depletion of CASP5 Ala90Thr heterozygous genotype in aged subjects. Exp Gerontol 2010; 45: 726–9PubMedCrossRef
95.
Soranzo N, Rendon A, Gieger C, et al. A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function. Blood 2009; 113: 3831–7PubMedCrossRef
96.
Johnson AD, Yanek LR, Chen MH, et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet 2010; 42: 608–13PubMedCrossRef
97.
Lin E, Tsai SJ. Gene-gene interactions in a context of individual variability in antipsychotic drug pharmacogenomics. Curr Pharmacogenomics Personalized Med 2011; 9: 323–31CrossRef
98.
99.
Rosenberg NA, Huang L, Jewett EM, et al. Genome-wide association studies in diverse populations. Nat Rev Genet 2010; 11: 356–66PubMedCrossRef
100.
Elbers CC, van Eijk KR, Franke L, et al. Using genome-wide pathway analysis to unravel the etiology of complex diseases. Genet Epidemiol 2009; 33: 419–31PubMedCrossRef
101.
Cantor RM, Lange K, Sinsheimer JS. Prioritizing GWAS results: a review of statistical methods and recommendations for their application. Am J Hum Genet 2010; 86: 6–22PubMedCrossRef
102.
Gayán J, González-Pérez A, Bermudo F, et al. A method for detecting epistasis in genome-wide studies using case-control multi-locus association analysis. BMC Genomics 2008; 9: 360PubMedCrossRef
103.
Jiang R, Tang W, Wu X, et al. A random forest approach to the detection of epistatic interactions in case-control studies. BMC Bioinformatics 2009; 10: S65PubMedCrossRef
104.
Tang W, Wu X, Jiang R, et al. Epistatic module detection for case-control studies: a Bayesian model with a Gibbs sampling strategy. PLoS Genet 2009; 5: e1000464PubMedCrossRef
105.
Wongseree W, Assawamakin A, Piroonratana T, et al. Detecting purely epistatic multi-locus interactions by an omnibus permutation test on ensembles of two-locus analyses. BMC Bioinformatics 2009; 10: 294PubMedCrossRef
106.
Emily M, Mailund T, Hein J, et al. Using biological networks to search for interacting loci in genome-wide association studies. Eur J Hum Genet 2009; 17: 1231–40PubMedCrossRef
107.
Yang HC, Liang YJ, Wu YL, et al. Genome-wide association study of young-onset hypertension in the Han Chinese population of Taiwan. PLoS One 2009; 4: e5459PubMedCrossRef
108.
Wan X, Yang C, Yang Q, et al. Predictive rule inference for epistatic interaction detection in genome-wide association studies. Bioinformatics 2010; 26: 30–7PubMedCrossRef
109.
Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 2010; 11: 415–25PubMedCrossRef
110.
Gorlov IP, Gorlova OY, Sunyaev SR, et al. Shifting paradigm of association studies: value of rare single-nucleotide polymorphisms. Am J Hum Genet 2008; 82: 100–12PubMedCrossRef
111.
Morris AP, Zeggini E. An evaluation of statistical approaches to rare variant analysis in genetic association studies. Genet Epidemiol 2010; 34: 188–93PubMedCrossRef
112.
Liu DJ, Leal SM. A novel adaptive method for the analysis of next-generation sequencing data to detect complex trait associations with rare variants due to gene main effects and interactions. PLoS Genet 2010; 6: e1001156PubMedCrossRef
113.
Wang CH, Hwang Y, Lin E. Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies. J Exper Pharmacol 2010; 2: 73–82CrossRef
114.
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401PubMedCrossRef
115.
Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100–4PubMedCrossRef
116.
Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 10: 1105–11CrossRef
117.
Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338–45PubMedCrossRef
118.
Fox BA, Sheppard PO, O’Hara PJ. The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family. PLoS One 2009; 4: e4933PubMedCrossRef
119.
Dellgren C, Gad HH, Hamming OJ, et al. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun 2009; 10: 125–31PubMedCrossRef
120.
Lin E, Hwang Y. A support vector machine approach to assess drug efficacy of interferon-alpha and ribavirin combination therapy. Mol Diagn Ther 2008; 12: 219–23PubMedCrossRef
121.
Ising M, Lucae S, Binder EB, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009; 66: 966–75PubMedCrossRef
122.
Garriock HA, Kraft JB, Shyn SI, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010; 67: 133–8PubMedCrossRef
123.
Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of anti-depressant response in the GENDEP project. Am J Psychiatry 2010; 167: 555–64PubMedCrossRef
124.
Laje G, McMahon FJ. Genome-wide association studies of antidepressant outcome: a brief review. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1553–7PubMedCrossRef
125.
Malhotra AK. The pharmacogenetics of depression: enter the GWAS. Am J Psychiatry 2010; 167: 493–5PubMedCrossRef
126.
Amos W, Driscoll E, Hoffman JI. Candidate genes versus genome-wide associations: which are better for detecting genetic susceptibility to infectious disease? Proc Biol Sci 2011; 278: 1183–8PubMedCrossRef
127.
Uher R, Huezo-Diaz P, Perroud N, et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009; 9: 225–33PubMedCrossRef
128.
Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141: 338–47PubMedCrossRef
129.
Huang LC, Hsu SY, Lin E. A comparison of classification methods for predicting chronic fatigue syndrome based on genetic data. J Transl Med 2009; 7: 81PubMedCrossRef
130.
Saeys Y, Inza I, Larrañaga P. A review of feature selection techniques in bioinformatics. Bioinformatics 2007; 23: 2507–17PubMedCrossRef
131.
Hsieh CH, Hung YJ, Pei D, et al. Pilot association study between a common variant in the non-muscle myosin heavy chain 9 (MYH9) gene and diabetic renal disease in a Taiwanese population with type 2 diabetes. Appl Clin Genet 2010; 3: 17–22
Metadata
Title
Assessing Gene-Gene Interactions in Pharmacogenomics
Authors
Hsien-Yuan Lane
Guochuan E. Tsai
Dr Eugene Lin
Publication date
01-02-2012
Publisher
Springer International Publishing
Published in
Molecular Diagnosis & Therapy / Issue 1/2012
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/BF03256426

Other articles of this Issue 1/2012

Molecular Diagnosis & Therapy 1/2012 Go to the issue

Current Opinion

Molecular Signatures of Lung Cancer

Current Opinion

Circulating Tumor Cells

News

From the Literature

Original Research Article

PARP1 Polymorphisms Increase the Risk of Gastric Cancer in a Chinese Population

Commentary

Sensitive Biomarkers of Cancer Recurrence and Metastasis: Inexpensive Tools to Cut Costs and Reduce Radiation Exposure among Cancer Patients

Original Research Article

Pharmacogenomics of Codeine, Morphine, and Morphine-6-Glucuronide
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits